Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome

Item Type:Article
Title:Granulocyte macrophage-colony stimulating factor plus interleukin-2 plus alpha-interferon plus 5-fluorouracil in the treatment of metastatic renal cell cancer: induction of CD80/86+ T cells indicates adverse outcome
Creators Name:Westermann, J. and Hecker, A.C. and Floercken, A. and Doerken, B. and Pezzutto, A.
Abstract:Even in the era of multitargeted therapies, cytokines remain at least one of different treatment options in renal cell cancer (RCC), particularly for patients belonging to the good prognostic risk category according to Memorial Sloan Kettering Cancer Center criteria. Granulocyte macrophage-colony stimulating factor plays a central role in the differentiation and activation of antigen presenting cells. This clinical phase 1/2 chemoimmunotherapy trial in metastatic RCC used sequential application of alpha-interferon /5-fluorouracil followed by granulocyte macrophage-colony stimulating factor/interleukin-2. The study was performed before multikinase inhibitors were available for routine use. Twenty patients with metastatic RCC were enrolled into this phase 1/2 protocol. Sequential chemoimmunotherapy was feasible and safe on an outpatient basis. The regimen had only modest antitumor activity with 4 mixed responses and 4 stable diseases being documented after 4 treatment cycles. Enhanced proliferative and stimulatory capacity of peripheral blood mononuclear cells was only observed in patients with mixed responses/stable diseases whereas patients with progressive disease did not show any change. Most interestingly, there was a significant increase of T cells expressing the costimulatory molecules CD80/86 in patients with progressive disease. This finding is reported here for the first time under chemoimmunotherapy of RCC. In conclusion, clinical response rates of this cytokine-based regimen do not justify further clinical evaluation. However, the study suggests that CD80/86 T cells might have negative regulatory function under cytokine treatment and are possibly useful as a negative predictive marker for clinical response.
Keywords:CD80 Antigens, CD86 Antigens, Antineoplastic Combined Chemotherapy Protocols, Cancer Vaccines, Renal Cell Carcinoma, Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, Interferon-alpha, Interleukin-2, Kidney Neoplasms, T-Lymphocytes
Source:Journal of Immunotherapy
ISSN:1524-9557
Publisher:Lippincott Williams & Wilkins (U.S.A.)
Volume:32
Number:6
Page Range:667-675
Date:July 2009
Official Publication:https://doi.org/10.1097/CJI.0b013e3181a950e5
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library